Well-known BRAF mutations have been reported in up to 20% of all types of cancers [3,4], and BRAF V600E targeting agents such as dabrafenib, vemurafenib, and encorafenib are used to treat melanoma, lung cancer, and colorectal cancer [5,6,7,8,9]. This evidence concerns the gene BRAF and lung carcinoma.